Personalized tumor-loaded monocyte-derived dendritic cell vaccination in combination with atezolizumab as maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC): phase Ib-II VENEZOLUNG trial.
A personalized vaccine made from each patient's own tumor cells shows early promise combined with immunotherapy for a deadly lung cancer type, warranting further investigation.
The VENEZOLUNG Phase Ib-II trial tested a fully personalized dendritic cell vaccine loaded with autologous tumor material combined with atezolizumab as maintenance in ES-SCLC, a disease with notoriously poor prognosis after initial response. Initial results suggest the combination is safe with preliminary activity signals, supporting further investigation of personalized cancer vaccination in ES-SCLC maintenance.
What the study was
- Study design
- Phase Ib-II single-arm trial (VENEZOLUNG trial)
- Population
- Patients with extensive-stage small cell lung cancer receiving maintenance treatment after platinum-etoposide-atezolizumab
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Journal for immunotherapy of cancer
Why it surfaced
Phase Ib-II VENEZOLUNG trial of personalized tumor-loaded DC vaccination + atezolizumab in ES-SCLC maintenance. ES-SCLC has dismal post-response prognosis; personalized cancer vaccines represent an emerging paradigm. Spanish multicenter consortium (Rosell R, Benitez-Ribas D).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.